Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
暂无分享,去创建一个
L. Schwartz | H. Scher | P. Marks | L. Krug | O. O’Connor | S. Olgac | T. Curley | V. Richon | W. Kelly | J. Chiao | M. Heaney | Barbara MacGregore-Cortelli | W. Tong | J. Secrist | S. Richardson | E. Chu | P. Marks | Semra Olgac | W. K. Kelly | Owen A. O'Connor | Lee M. Krug | J. Paul Secrist
[1] Katia Basso,et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. , 2003, Blood.
[2] C. Monneret,et al. Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.
[3] F. Sherman,et al. The diversity of acetylated proteins , 2002, Genome Biology.
[4] C. Van Lint,et al. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.
[5] T. Fojo,et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. , 2001, The Journal of clinical endocrinology and metabolism.
[6] Robert Tjian,et al. Regulating the Regulators Lysine Modifications Make Their Mark , 2003, Cell.
[7] Matty P. Weijenberg,et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.
[8] H. Scher,et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] F. Ece,et al. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. , 2001, American journal of respiratory cell and molecular biology.
[10] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] T. Kouzarides. Histone methylation in transcriptional control. , 2002, Current opinion in genetics & development.
[12] V. Della Pietra,et al. Genes modulated by histone acetylation as new effectors of butyrate activity , 2001, FEBS letters.
[13] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[14] T. Endo,et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. , 2004, Endocrinology.
[15] Y. Furukawa,et al. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Schwartz,et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] Wei Gu,et al. Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.